Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
Aktis Oncology (AKTS) had its price target raised by HC Wainwright from $30.00 to $33.00. They now have a "buy" rating on the stock.
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
Aktis Oncology (AKTS) is now covered by HC Wainwright. They set a "buy" rating and a $30.00 price target on the stock.
Aktis Oncology to Present at Upcoming March Investor Conferences